IVF

Auto Added by WPeMatico

Kindbody raises $15M, will open a ‘Fertility Bus’ with mobile testing & assessments

Kindbody, a startup that lures millennial women into its pop-up fertility clinics with feminist messaging and attractive branding, has raised a $15 million Series A in a round co-led by RRE Ventures and Perceptive Advisors.

The New York-based company was founded last year by Gina Bartasi, a fertility industry vet who previously launched Progyny, a fertility benefit solution for employers, and FertilityAuthority.com, an information platform and social network for people struggling with fertility.

“We want to increase accessibility,” Bartasi told TechCrunch. “For too long, IVF and fertility treatments were for the 1 percent. We want to make fertility treatment affordable and accessible and available to all regardless of ethnicity and social economic status.”

Kindbody operates a fleet of vans — mobile clinics, rather — where women receive a free blood test for the anti-Müllerian hormone (AMH), which helps assess their ovarian egg reserve but cannot conclusively determine a woman’s fertility. Depending on the results of the test, Kindbody advises women to visit its brick-and-mortar clinic in Manhattan, where they can receive a full fertility assessment for $250. Ultimately, the mobile clinics serve as a marketing strategy for Kindbody’s core service: egg freezing.

Kindbody charges patients $6,000 per egg-freezing cycle, a price that doesn’t include the cost of necessary medications but is still significantly less than market averages.

Bartasi said the mobile clinics have been “wildly popular,” attracting hoards of women to its brick-and-mortar clinic. As a result, Kindbody plans to launch a “fertility bus” this spring, where the company will conduct full fertility assessments, including the test for AMH, a pelvic ultrasound and a full consultation with a fertility specialist.

In other words, Kindbody will offer all components of the egg-freezing process on a bus aside from the actual retrieval, which occurs in Kindbody’s lab. The bus will travel around New York City before heading west to San Francisco, where it plans to park on the campuses of large employers, catering to tech employees curious about their fertility.

“Our mission at Kindbody is to bring care directly to the patient instead of asking the patient to come to visit us and inconvenience them,” Bartasi said.

A sneak peek of Kindbody’s “fertility bus,” which is still in the works

Kindbody, which has raised $22 million to date from Green D Ventures, Trailmix Ventures, Winklevoss Capital, Chelsea Clinton, Clover Health co-founder Vivek Garipalli and others, also provides women support getting pregnant with in vitro fertilisation (IVF) and intrauterine insemination (IUI). 

With the latest investment, Kindbody will open a second brick-and-mortar clinic in Manhattan and its first permanent clinic in San Francisco. Additionally, Bartasi says they are in the process of closing an acquisition in Los Angeles that will result in Kindbody’s first permanent clinic in the city. Soon, the company will expand to include mental health, nutrition and gynecological services.

In an interview with The Verge last year, Bartasi said she’s taken inspiration from SoulCycle and DryBar, companies whose millennial-focused branding strategies and prolific social media presences have helped them accumulate customers. Kindbody, in that vein, notifies its followers of new pop-up clinics through its Instagram page.

In the article, The Verge called Kindbody “the SoulCycle of fertility” and questioned its branding strategy and its claim that egg freezing “freezes time.” After all, there is limited research confirming the efficacy of egg freezing.

“The technology that allows for egg-freezing has only been widely used in the last five to six years,” Bartasi explained. “The majority of women who froze their eggs haven’t used them yet. It’s not like you freeze your eggs in February and meet Mr. Right in June.”

Though Kindbody touts a mission of providing fertility treatments to the 99 percent, there’s no getting around the sky-high costs of the services, and one might argue that companies like Kindbody are capitalizing off women’s fear of infertility. Providing free AMH tests, which often falsely lead women to believe they aren’t as fertile as they’d hoped, might encourage more women to seek a full-fertility assessment and ultimately, to pay $6,000 to freeze their eggs, when in reality they are just as fertile as the average woman and not the ideal candidate for the difficult and uncomfortable process.

Bartasi said Kindbody makes all the options clear to its patients. She added that when she does hear accusations that services like Kindbody capitalize on fear of infertility, they tend to come from legacy programs and male fertility doctors: “They are a little rattled by some of the new entrants that look like the patients,” she said. “We are women designing for women. For far too long women’s health has been solved for by men.”

Kindbody’s pricing scheme may itself instill fear in incumbent fertility clinics. The startup’s egg-freezing services are much cheaper than market averages; its IVF services, however, are not. Not including the costs of medications necessary to successfully harvest eggs from the ovaries, the average cost of an egg-freezing procedure costs approximately $10,000, compared to Kindbody’s $6,000. Its IVF services are on par with other options in the market, costing $10,000 to $12,000 — not including medications — for one cycle of IVF.

Kindbody is able to charge less for egg freezing because they’ve cut out operational inefficiencies, i.e. they are a tech-enabled platform while many fertility clinics around the U.S. are still handing out hoards of paperwork and using fax machines. Bartasi admits, however, that this means Kindbody is making less money per patient than some of these legacy clinics.

“What is a reasonable profit margin for fertility doctors today?” Bartasi said. “Historically, margins have been very, very high, driven by a high retail price. But are these really high retail prices sustainable long term? If you’re charging 22,000 for IVF, how long is that sustainable? Our profit margins are healthy.”

Bartasi isn’t the only entrepreneur to catch on to the opportunity here, as I’ve noted. A whole bunch of women’s health startups have launched and secured funding recently.

Tia, for example, opened a clinic and launched an app that provides health advice and period tracking for women. Extend Fertility, which like Kindbody, helps women preserve their fertility through egg freezing, banked a $15 million round. And a startup called NextGen Jane, which is trying to detect endometriosis with “smart tampons,” announced a $9 million Series A a few weeks ago.

Powered by WPeMatico

Mira launches a device for more accurate fertility testing in the home

Mira, launching today at TechCrunch Disrupt SF 2018, is a new device that aims to help women who are struggling to conceive. The Mira Fertility system offers personalized cycle prediction by measuring fertility hormone concentrations in urine samples, telling women which days they’re fertile. The system is more advanced and accurate than the existing home test kits, the company claims, which can be hard to read and aren’t personalized to the individual.

The company behind Mira, Quanovate, was founded in late 2015 by a group of scientists, engineers, OBGYN doctors, and business execs to solve the problem of the unavailability of advanced home health testing.

“I have a lot of friends who, like me, [prioritized] their career advancement and higher education, and they tended to delay their maternal age,” explains Mira co-founder and CEO Sylvia Kang. “But there’s no education for them about when to try for a baby, and they have no awareness about their fertility health,” she says.

Kang received an MBA at Cornell Johnson, went to Columbia for an MS in Biomedical engineering and received at PhD in Biophysics from University of Pittsburgh, before working as a Business Director at Corning where she was responsible for $100 million in global P&L, which she left to start Mira.

She says that women’s hormones are changing daily, and everyone’s profiles differ due to their lifestyle, stress levels and other factors. The only way to accurately track fertile days, then, is through continuous testing – something that’s been difficult to do at home.

 

To solve this problem, the team worked to develop the Mira system, which includes a small home analyzer, urine test strips, and an accompanying mobile application. The home analyzer miniaturizes lab equipment for home use, and brings down the cost.

To use the system, the woman places the test strip into the device which then uses immunofluorescence technology to read the results. Currently, the device tests for the presence of luteinizing hormone (LH), which is an indicator of ovulation. However, the company has already has plans to update the device so it can test for other hormones in the near future. (It’s FDA-cleared to detect estrogen, for example, but that won’t be available at launch.)

The system instead is $199 and ships with 10 test strips. After analyzing the strip, information about the hormone levels is displayed on the screen and sent to the Mira app via Bluetooth.

The app offers women more information about what this data means – like whether they should attempt to conceive today or wait. A subscription service will also offer them access to doctors so they can ask questions, but this will be free at launch.

“This technology is completely different from all the test strips on the market. It’s more accurate, but more importantly, this one is quantitative – that means we give you your actual, formal concentrations,” says Kang. “The [existing] tests strips only give you positive or negative. Since we have your numbers, our A.I. can do pattern recognition. Our algorithm prediction is based on your pattern specifically, not the average of all the population.”

 

What this means, in practice, is that women struggling to conceive will have more accurate, more actionable, and more personalized results with Mira. During a clinical trial with 400 patient samples, Mira reached 99 percent accuracy, compared with lab equipment, the company says. They also have 18 IPs covering hardware, software, database management and more, including utility patents and models, design patents, trademarks and copyrights.

The company is now working on a portal for doctors, so they could access their own patients’ data for further analysis. Mira may also eventually make its collected data, once anonymized, available to researchers, as well. But Kang says no formal decisions have been made on that front yet.

Longer-term, Kang explains that the same system can be adapted to track pregnancy and menopause, and eventually similar technology could be put to use for analyzing other conditions, like those related to kidney problems or the thyroid.

The Pleasanton, Calif.-based company, is currently a team of 36 and has raised $4.5 million from investors including Gopher Ventures, and two other cross-border investors Mira doesn’t want to disclose publicly.

At Disrupt, the company announced the Mira device is now available for pre-order and will begin shipping in October 2018.

It’s sold online via the Mira website, but is in discussions with doctors and retailers to broaden its availability going forward.

Powered by WPeMatico